Protara Therapeutics Inc - Prakiraan pendapatan perusahaan TARA
Protara Therapeutics (TARA) target sales volumes on the GURU.Markets chart demonstrate growth dynamics, where 0.00 reflects the latest metric value. The asset relies on strong pricing power within the orphan drug segment. The strategy is based on optimizing R&D expenses for the licensing of cell therapies. Management's scientific discipline ensures the proficient administration of programs for treating rare oncological pathologies.
Rincian analitis perusahaan Protara Therapeutics
- nilai saham lan prakiraan konsensus rega:
- rincian nilai pasar emiten:
- data ekuitas miturut neraca:
- indikator beban utang lan likuiditas:
Total Utang marang Modal Protara Therapeutics|TARA - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Protara Therapeutics|TARA - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Protara|TARA - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Protara Therapeutics|Indikator likuiditas cepet protaratx.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
TARA - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Protara Therapeutics|TARA - Nilai perusahaan marang bathi resik|Pangali Forward P/E protaratx.com|TARA - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Protara Therapeutics|TARA - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Protara Therapeutics|TARA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan protaratx.com|TARA - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Protara Therapeutics
- data dodolan lan asil:
Pambiji fundamental:protaratx.com
The modernization of ventilation systems and the full capacity utilization of Protara Therapeutics (TARA) laboratories determine the current scaling potential for cell therapy production. An analysis of the organization's projected commercial revenue allows for an assessment of business expansion speed through the calculation of expected cash flows; however, steady growth in the product line may mask the risk of overpaying for the asset amid inflated long-term investor consensus expectations.
Analisis perusahaan pesaing
Prakiraan volume dodolan ONC|HALO (Halozyme) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan RVMD (revmed.com)|Dodolan mangsa ngarep perusahaan Ascentage (AAPG)|CGON: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan UroGen Pharma Ltd.|BCAX: Prakiraan volume dodolan|PSNL - Dodolan mangsa ngarep perusahaan|ERAS (Erasca Oncology) - Prakiraan volume dodolan|Prakiraan volume dodolan Delcath Systems, Inc.|Prakiraan pendapatan perusahaan ymabs.com (YMAB)|Prakiraan pendapatan perusahaan AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Volume dodolan mangsa ngarep perusahaan|Accuray Inc. (ARAY) - Volume dodolan sing dikarepake perusahaan|SELLAS Life Sciences Group, Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Prakiraan pendapatan perusahaan|HURA - Dodolan mangsa ngarep perusahaan|FATE (fatetherapeutics.com) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Aadi Bioscience Inc (WHWK)|Prakiraan volume dodolan TCRX|CSBR - Volume dodolan sing dikarepake perusahaan|Prakiraan volume dodolan XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Volume dodolan sing dikarepake perusahaan|OSTX: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan RADX (Radiopharm Theranostics)|Artiva (ARTV) - Prakiraan pendapatan perusahaan|ANL: Prakiraan volume pendapatan perusahaan|VERU (Veru Corporation) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Tempest Therapeutics, Inc. TPST|Prakiraan volume dodolan XLO|Renovaro - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Mural Bio MURA|KAPA: Prakiraan pendapatan perusahaan|OnKure Therapeutics - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan w2.cytomed.sg GDTC|CRIS: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Apollomics Inc.|THAR (Tharimmune Corporation) - Prakiraan volume dodolan|Prakiraan volume dodolan Advanced Biomed Inc|Prakiraan volume dodolan GNPX|Volume dodolan mangsa ngarep perusahaan Calidi Biotherapeutics Inc. CLDI|Prakiraan pendapatan perusahaan Sunshine Biopharma Inc. SBFM|Dodolan mangsa ngarep perusahaan Xenetic Biosciences (XBIO)|SLRX - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Kitov Pharma|AON (AONC) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan BeiGene|Prakiraan pendapatan perusahaan checkpointtx.com|Prakiraan pendapatan perusahaan ELEV (Elevation Oncology)|Prakiraan volume dodolan ICAD|Ikena Oncology - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Notable Labs, Ltd. NTBL|VIRX: Prakiraan pendapatan perusahaan|MOR - Prakiraan pendapatan perusahaan|NAYA Bio (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan
